Dr Laurent Audoly joins Pieris

pharmafile | June 9, 2010 | Appointment | Research and Development Pieris, appointment, research and development 

French biotech company Pieris has appointed Dr Laurent Audoly as chief scientific officer.

Dr Audoly was most recently biologics research site lead at Merck & Co, and has both pharma and biotech experience, with extensive expertise in therapeutic protein drug development.

“As a keen proponent of targeted therapeutic technologies, I am excited to join Pieris at a stage where the Anticalin approach is beginning to demonstrate its great therapeutic potential,” he said. “My goal is to combine my experience from big pharma and biotech with the capabilities present at Pieris to bring the full spectrum of R&D operations to the next level.”

Dr Audoly has held research and managerial positions of increasing responsibility, first as senior research scientist in the department of inflammation at Pfizer and then as senior research fellow in the department of pharmacology at Merck & Co.

Following his first stint at Merck Laurent joined MedImmune as director of inflammation R&D before returning to Merck as biologics research site lead.

Related Content

sarah_mcdonald

Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

white_and_ford

Abbott CEO to step down after 21 years

After more than two decades at the head of the company, it has emerged that …

funk

Lonza CEO to step down in 2020

It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …

Latest content